<DOC>
	<DOCNO>NCT02060916</DOCNO>
	<brief_summary>This study evaluate effect PAZ320 post-prandial glucose excursion measure via continuous glucose monitoring adverse effect profile human .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy PAZ320 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>In study , investigator seek evaluate effect PAZ320 post-prandial glucose excursion measure via continuous glucose monitoring adverse effect profile human . Continuous glucose monitor ( CGM ) minimally invasive device measure glucose level interstitial fluid . A small wire insert subcutaneously transmits ambient subcutaneous glucose concentration every 5 minute wireless recorder . In usual use , patient see data graph previous 1 , 3 9 hour identify trend look back time ( ie night ) . In study , patient blind data confound result , note another study patient 's blood sugar control well able see CGM result modify diet . CGM 's show clinical accuracy 95.5-98.9 % use clinical trial find safe . Having patient finger-stick glucose intermittently time wear CGM improve accuracy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject , age 1875 year ; Subjects diagnose Type 2 Diabetes mellitus ; Subjects currently oral agent insulin ; Body mass index 25 40 kg/m2 ; Subjects able comply study procedure sign inform consent A1c le equal 9 % Medication ( diabetes medication insulin ) dietary supplement know affect glucose galactose metabolism Use acetaminophencontaining product Lactose galactose intolerance History eat disorder Food allergy severe food intolerance Pregnant lactate female Subjects diabetes mellitus treat high dose sulfonylurea ( glyburide &gt; 20 mg/day , , glimepiride &gt; 8 mg per day , glipizide &gt; 20 mg per day ) Î±glucosidase inhibitor ( acarbose ) , meglitinides ( repaglinide &gt; 6 mg per day ) ) , ; Subject gastrointestinal disease may interfere absorption investigational product discretion investigator , include limited malabsorption syndrome gastric ulcer ; Subject receive investigational agent within 30 day prior first dose investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>